Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva and Ranbaxy win FDA approval for generic Zocor
As the first company to file an abbreviated new drug application for the 5mg, 10mg, 20mg and 40mg strengths, Teva has been awarded 180 days of marketing exclusivity.
As the first company to file an abbreviated new drug application for the 5mg, 10mg, 20mg and 40mg strengths, Teva has been awarded 180 days of marketing exclusivity.
The data, presented at the 88th annual meeting of the Endocrine Society, highlights the potential of this marker, but the company said that more research is needed to
A randomized, double-blind study of 37 healthy subjects was conducted to evaluate the efficacy of VEC-162 (10, 20, 50 and 100mg) in a model of transient insomnia. The
ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone. The company hopes that the once-per-week dosing of the product will offer a benefit
The Lumigan first-line indication is in addition to the product’s already established use as a second-line treatment, for which the FDA approved the drug in 2001. Since its
CHS Resources will develop and ultimately commercialize patent pending technology for the treatment of skin cancer. The technology was discovered by Dr Herbert Weissbach, director of the Center
The trial is expected to enroll approximately 100 patients at multiple sites in the US. Patients will be evaluated for a total of nine weeks including a four-week
The newly approved products are the extended-release (ER) and immediate-release formulations of oxymorphone hydrochloride. Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous,
The first analysis demonstrated the ability of Humira to maintain the reduction of signs and symptoms in ankylosing spondylitis (AS) patients at 12 weeks through 52 weeks of
The collaboration will encompass the development of therapeutic antibodies against proteins identified by Celera’s proteomic research discovery efforts as being over-expressed on the surface of tumor cells and